How International Healthcare Leaders are Transforming Health Systems at Speed and Scale

Session Focus

Mellish structured the conversation around five elements in sequence: platform, problem, people, process and performance. The panel brought together a specialist tertiary hospital, a university teaching hospital network and a city-scale healthcare ecosystem, with Saudi Arabia and China both represented as systems pursuing rapid transformation.

He noted that Saudi Arabia operates what has been recognized as the largest virtual health network in the world, now in its fifth or sixth year, and that China leads in AI and AI agent hospitals under development.

Platform: How Institutions Influence the Wider System

Bjorn Zoëga MD, PhD began from the problem most systems share, which is fragmentation and the question of whether a patient is in the right part of the system at the right time. As a not-for-profit hospital that is not government-owned, King Faisal has been commissioned to take the most complicated cases.

Concentrating difficult cases produces critical mass in conditions that are individually rare but collectively not rare at all, which in turn generates information the international community can learn from. The hospital now handles 25 percent of all cancer cases in the kingdom, weighted heavily toward the most difficult.

He was explicit about the frame of reference. The hospital is not a showcase for Saudi Arabia or the Gulf region. It is an international showcase, and he argued that is the only way to move forward, because being the best in your own area with nothing to compare against breeds complacency. Clinical research volume has increased roughly six-fold in two and a half years.

Haipeng Xiao MD, PhD described a system of three campuses, roughly 3,500 beds and 15,000 to 20,000 outpatients a day, ranked third in China on both the Nature health science index and the BMJ research index, and designated one of eight national medical centers.

Adel AlMarshad MD described a different kind of platform. The Royal Commission for Riyadh City is responsible for integrating healthcare across the city, understanding demand and reimagining delivery against rising population, tourism and residency. Large development projects create the opportunity to place care differently.

He identified three specific goals: complementing the work of pinnacle referral hospitals, meeting the needs of patients currently receiving care overseas along with trainees educated abroad, and participating in the biotechnology transformation underway across the kingdom. He noted an MOU signed with Mass General Brigham, announced during the Saudi state visit, and described the Riyadh model as replicable across other cities in the kingdom and potentially the region.

Problem: Where the Bottlenecks Sit

AlMarshad named the lag between global discovery and local availability. Innovation takes a very long time to move from discovery through development and bedside proof of efficacy into mainstream practice, and longer still to reach his part of the world. He framed the aspiration in consumer terms: something closer to the immediate update cycle of a smartphone, integrated into clinical pathways. Closing that outcome gap is why he is pursuing research, education and clinical excellence together.

Xiao described a demographic and workforce problem at national scale. By 2030 China will have roughly 486 million people over 65, a number he noted exceeds the total population of Europe. Physician density is about 3.7 per thousand and nursing density about 4 per thousand, both well below OECD levels, against a rising burden of diabetes, obesity, cancer and cardiovascular disease.

The consequence is maldistribution. Qualified physicians concentrate in tertiary centers, which overcrowd, while grassroots institutions remain underused. Patients travel hundreds or thousands of miles to reach a top center.

Zoëga gave the same answer he would give anywhere he has worked, in Sweden or Saudi Arabia: administration that treats innovation as an enemy. He was pointed about innovation offices, describing one at Karolinska staffed by people doing innovation who were not doing any innovation. Innovation happens close to the patient. Ethical review is not what he means by administration.

The DNA Model

Xiao described the response his hospital designed, which he was careful to say is not a gimmick. D is doctors, N is nurses, A is AI and other high technology, used as three enablers.

The center anchors the model and partners with leading institutions including Mass General Brigham. It sends doctors and nurses with leadership capacity out to community hospitals, then uses AI, robotic surgery, remote robotic surgery, internet hospital and hospital-at-home capabilities to raise the capability of regional and grassroots institutions.

The worked example: a cancer patient in a rural area, a treatment plan developed in consultation with an MGB physician, and a robotic procedure performed remotely for pancreatic cancer. He described completing the first global case of this kind using multi-robotic surgery.

The scale figures: eight DNA alliance hospitals directly supported, another 100 lower-level community hospitals supported through them, more than 45,000 frontline workers trained, and referrals reduced by 30 percent.

He was emphatic that the efficiency gain returns to clinicians and patients rather than being converted into higher patient volume.

Clearing the Path for Clinicians

Zoëga illustrated his position with two cases from Karolinska. A heart surgeon approached him a few months into his tenure with a proposal to perform a fully robotic heart transplant, noting the training would not require additional money. Zoëga told him to do it. Half a year later the first fully robotic heart transplant in the world had been performed, through a small incision rather than an opened chest, and the patient went home in six days.

A neurosurgeon came to him with a similar robotics-inspired idea, in a department he did not oversee. Roughly five months later the team completed the first fully robotic removal of a brain tumor, and that patient went home within 24 hours.

His account of his own role was modest: remove the administrative and bureaucratic barriers, maintain the ethical review, and let the people next to the patient do the work.

Talent as a Conduit for Standards

AlMarshad, who spent 20 years in the United States across Colorado, George Washington, Yale New Haven, Harvard’s school of public health and UC San Diego before returning to Saudi Arabia, argued that physicians trained abroad are the real mechanism by which care standards travel.

His broader observation was that American academic medical centers have barely begun to operate internationally relative to what is possible.

Key Takeaways

1. Concentrating complex cases creates a research asset. Volume in rare conditions produces knowledge the international community can use.

2. Demographics are outrunning workforce capacity. China faces 486 million people over 65 by 2030 against physician density well below OECD levels.

3. Administration is the named bottleneck, not technology. Removing bureaucratic barriers produced two world-first robotic procedures within months.

4. Technology transfer should raise grassroots capability. The DNA model pushes capacity outward rather than pulling patients inward.

5. Efficiency gains should return to clinicians. Xiao was explicit that saved time is not converted into higher volume.

6. The lag from discovery to local practice is the equity problem. Closing the outcome gap requires research, education and clinical excellence together.